Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Morphosys AG (GB:0NDV)
LSE:0NDV
Holding GB:0NDV?
Track your performance easily
0NDV Stock Chart & Stats
Day’s Range€67.6 - €67.6
52-Week Range― - ―
Previous Close€67.6
Volume0.00
Average Volume (3M)N/A
Market Cap
€2.53B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€68.00Price Target Upside0.59% Upside
Rating ConsensusHold
Number of Analyst Covering1
Morphosys News
Bulls Say, Bears Say
Bulls Say
AcquisitionThe company confirms the acquisition deal with NVS is on track to close in 1H.
Analyst RecommendationReiterate MP and €68 PT based on NVS acquisition.
Product DevelopmentThe NDA filing for pelabresib is expected in 2H.
Bears Say
Clinical Safety ConcernsPhysicians involved in the trial disclosed multiple cases of AML transformation in the Phase 3 MANIFEST-2.
Potential Deal TerminationIf a warning letter was issued, it is possible that Novartis could choose to leverage certain clauses to justify termination of the deal.
Regulatory IssuesA warning letter was issued by the FDA to physicians involved in the MANIFEST-2 trial.
---
0NDV FAQ
What was Morphosys AG’s price range in the past 12 months?
Currently, no data Available
What is Morphosys AG’s market cap?
Currently, no data Available
When is Morphosys AG’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Morphosys AG’s earnings last quarter?
Currently, no data Available
Is Morphosys AG overvalued?
According to Wall Street analysts Morphosys AG’s price is currently Undervalued.
Does Morphosys AG pay dividends?
Morphosys AG does not currently pay dividends.
What is Morphosys AG’s EPS estimate?
Morphosys AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Morphosys AG have?
Currently, no data Available
What happened to Morphosys AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Morphosys AG?
Currently, no hedge funds are holding shares in GB:0NDV
---
Morphosys Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
145.81%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-17.85%
Trailing 12-Months
Company Description
Morphosys AG
MorphoSys AG is a biotechnology company that develops therapeutic antibodies. The company reports two business segments: partnered discovery and proprietary development. Its partnered discovery segment applies the research, development, and optimization of antibody-drug candidates in partnerships with pharmaceutical and biotechnology companies. MorphoSys' profits in this segment stem from successful programs via milestone payments and potential royalties on product sales. In its proprietary development segment, the company develops antibodies that concentrate on inflammatory and autoimmune diseases, as well as cancer and infectious diseases.
---
0NDV Stock 12 Month Forecast
Average Price Target
€68.00
▲(0.59% Upside)
Technical Analysis
Best Analysts Covering 0NDV
1 Year
1 Year Success Rate
15/32 ratings generated profit
1 Year Average Return
+13.87%
reiterated a buy rating 10 months ago
Copying James Gordon's trades and holding each position for 1 Year would result in 46.88% of your transactions generating a profit, with an average return of +13.87% per trade.
---